JMS: Overview of Q1 2025 earnings report.
JMS: Announcements of individual stocks regarding the exclusive sales and cooperation agreement with Terumo Shanghai.
JMS: Teijin Pharma and JMS signed an agreement to establish a joint venture focusing on peritoneal dialysis
JMS: Notice regarding the formulation of a medium-term management plan
JMS: 2024 financial results overview
JMS: Notice regarding personnel changes
JMS: Summary of Financial Results for the third quarter 2024
JMS: Summary of Financial Results for the second quarter 2024
JMS: Notice regarding changes in subsidiary companies (acquisition of investment shares) in subsidiaries, etc.
JMS: Notice Concerning Organizational Reforms and Changes in Officers
JMS: Notice of compliance with Prime Market listing maintenance standards and selection applications and compliance status for the Standard Market
JMS: Notice of business partnership related to anticancer drug treatment
JMS: Summary of Financial Results 2023
JMS: Notice regarding partial changes and continuation of the response policy (takeover defense measures) relating to large-scale purchases of the Company's shares
JMS: Notice regarding transition to a company with an Audit and Supervisory Committee and partial changes to the Articles of Incorporation
JMS: Certified by the Ministry of Economy, Trade and Industry “Excellent Health Management Corporation 2023”
JMS: Notice Concerning Organizational Reforms and Personnel Changes
JMS: Notice regarding partial replacement of members of the Independent Committee based on the Response Policy (Takeover Defense Measures) relating to large-scale purchases of the Company's shares
JMS: Articles of association 2023-03-01
JMS: Summary of Financial Results for the third quarter 2023
No Data
No Data